Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: July 15, 2009
Reporting Period: Second Quarter 2009
Abbott Laboratories filed this report to announce its results of operations for the second quarter of 2009. The detailed financial results are furnished as Exhibit 99.1 (Press Release) and incorporated by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced Exhibit 99.1 (Press Release) which is not included in the provided text.
The company utilizes non-GAAP financial measures, including:
- Net earnings excluding specified items.
- Diluted earnings per common share excluding specified items.
These measures adjust for unusual or unpredictable factors such as acquisition-related costs, cost reduction initiatives, litigation and tax settlements, product launch costs, acquired in-process research and development, and gains/losses on certain investments.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Management Commentary
Management Commentary: Abbott's management believes the presentation of non-GAAP financial measures provides useful information to investors regarding ongoing business performance and is used internally to monitor business performance. However, management cautions investors to consider these measures in addition to, and not as a substitute for, GAAP financial measures.
Guidance and Risks: The filing text does not contain specific forward-looking guidance, risk factors, or contingencies beyond the general caution regarding non-GAAP measures.
Important Facts for Investor Verification
- Verify the specific GAAP and non-GAAP financial results for Q2 2009 in the referenced Press Release (Exhibit 99.1).
- Review the reconciliation between GAAP and non-GAAP measures to understand the impact of specified items (e.g., litigation, acquisition costs).
- Confirm the specific adjustments made to net earnings and diluted earnings per share.